Thierry Levade

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8997000/publications.pdf

Version: 2024-02-01

57	2,734	186265	189892
papers	citations	28 h-index	50 g-index

59	59	59	3565
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A diagnosis of progressive myoclonic ataxia guided by blood biomarkers. Parkinsonism and Related Disorders, 2022, 94, 124-126.	2.2	0
2	Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses. , 2022, , 735-764.		1
3	A case of <scp>ASAH1</scp>â€related pure SMA evolving into adultâ€onset Farber disease. Clinical Genetics, 2021, 100, 234-235.	2.0	3
4	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	4.1	15
5	Concise asymmetric synthesis of new enantiomeric C-alkyl pyrrolidines acting as pharmacological chaperones against Gaucher disease. Organic and Biomolecular Chemistry, 2020, 18, 7852-7861.	2.8	12
6	Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report. American Journal of Medical Genetics, Part A, 2020, 182, 2369-2371.	1.2	4
7	Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers, 2020, 12, 475.	3.7	13
8	First Report of a Patient with MPS Type VII, Due to Novel Mutations in GUSB, Who Underwent Enzyme Replacement and Then Hematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences, 2019, 20, 5345.	4.1	10
9	Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors. Molecules, 2019, 24, 354.	3.8	5
10	Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Frontiers in Pharmacology, 2019, 10, 443.	3.5	22
11	Inherited monogenic defects of ceramide metabolism: Molecular bases and diagnoses. Clinica Chimica Acta, 2019, 495, 457-466.	1.1	2
12	Allogeneic hematopoietic cell transplantation in Farber disease. Journal of Inherited Metabolic Disease, 2019, 42, 286-294.	3.6	13
13	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Molecular Cancer Therapeutics, 2019, 18, 289-300.	4.1	25
14	Pregnancy outcome in Refsum disease: Affected fetuses and children born to an affected mother. JIMD Reports, 2019, 46, 11-15.	1.5	0
15	Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L406-L420.	2.9	26
16	Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet Journal of Rare Diseases, 2018, 13, 121.	2.7	91
17	PNPLA1 defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain PNPLA1 irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. Human Molecular Genetics, 2017, 26, 1787-1800.	2.9	47
18	Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities. American Journal of Pathology, 2017, 187, 864-883.	3.8	41

#	Article	IF	Citations
19	Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 386-394.	3.8	35
20	A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences, 2017, 18, 441.	4.1	497
21	Role of Sphingolipids in Death Receptor Signalling. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 229-245.	0.1	0
22	Brief Report: Peripheral Osteolysis in Adults Linked to ASAH1 (Acid Ceramidase) Mutations: A New Presentation of Farber's Disease. Arthritis and Rheumatology, 2016, 68, 2323-2327.	5.6	17
23	Glucosylceramidases and malignancies in mammals. Biochimie, 2016, 125, 267-280.	2.6	36
24	Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses. , 2016, , 551-575.		3
25	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget, 2016, 7, 71873-71886.	1.8	35
26	Monogenic neurological disorders of sphingolipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1040-1051.	2.4	25
27	Human genetic disorders of sphingolipid biosynthesis. Journal of Inherited Metabolic Disease, 2015, 38, 65-76.	3.6	29
28	Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 31.	2.7	33
29	Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. Neuromuscular Disorders, 2015, 25, 959-963.	0.6	32
30	Basics of Sphingolipid Metabolism and Signalling. , 2015, , 1-20.		4
31	Dysregulation of Sphingolipid Metabolism in Melanoma: Roles in Pigmentation, Cell Survival and Tumor Progression. , 2015, , 123-139.		2
32	Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. Journal of Inherited Metabolic Disease, 2013, 36, 1079-1080.	3.6	23
33	Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene. Molecular Genetics and Metabolism, 2013, 109, 276-281.	1.1	25
34	Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Molecular Medicine, 2013, 5, 827-842.	6.9	90
35	The nonlysosomal Î²â€glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB Journal, 2013, 27, 489-498.	0.5	39
36	Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1. American Journal of Human Genetics, 2012, 91, 5-14.	6.2	250

#	Article	IF	Citations
37	Acid Ceramidase Expression Modulates the Sensitivity of A375 Melanoma Cells to Dacarbazine. Journal of Biological Chemistry, 2011, 286, 28200-28209.	3.4	71
38	Danon disease: intrafamilial phenotypic variability related to a novel LAMP-2 mutation. Journal of Inherited Metabolic Disease, 2011, 34, 515-522.	3.6	12
39	Autologous Transplantation of Lentivector/Acid Ceramidaseâ€"Transduced Hematopoietic Cells in Nonhuman Primates. Human Gene Therapy, 2011, 22, 679-687.	2.7	34
40	A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease. Journal of Lipid Research, 2010, 51, 3542-3547.	4.2	53
41	IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis. PLoS ONE, 2009, 4, e7929.	2.5	75
42	Disruption of Sphingosine 1-Phosphate Lyase Confers Resistance to Chemotherapy and Promotes Oncogenesis through Bcl-2/Bcl-xL Upregulation. Cancer Research, 2009, 69, 9346-9353.	0.9	103
43	The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochemical Pharmacology, 2009, 78, 477-485.	4.4	99
44	Highly Regioselective Oxirane Ringâ€Opening of a Versatile Epoxypyrrolidine Precursor of New Iminoâ€Sugarâ€Based Sphingolipid Mimics. European Journal of Organic Chemistry, 2009, 2009, 2474-2489.	2.4	15
45	Danon disease: Further clinical and molecular heterogeneity. Muscle and Nerve, 2009, 39, 837-844.	2.2	15
46	Recommendations on the diagnosis and management of Niemann-Pick disease type C. Molecular Genetics and Metabolism, 2009, 98, 152-165.	1.1	210
47	In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Molecular Genetics and Metabolism, 2008, 95, 133-141.	1.1	32
48	Functions of sphingolipid metabolism in mammals â€" Lessons from genetic defects. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 145-183.	2.4	62
49	Synthesis of a Novel Ceramide Analogue and its Use in a High-Throughput Fluorogenic Assay for Ceramidases. ChemBioChem, 2007, 8, 642-648.	2.6	53
50	C-Alkyl 5-membered ring imino sugars as new potent cytotoxic glucosylceramide synthase inhibitors. Organic and Biomolecular Chemistry, 2006, 4, 4437-4439.	2.8	22
51	Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 2104-2120.	2.6	116
52	The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB Journal, 2003, 17, 1144-1146.	0.5	45
53	Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscular Disorders, 2002, 12, 882-885.	0.6	41
54	Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. International Journal of Cancer, 2001, 94, 157-165.	5.1	110

#	Article	IF	Citations
55	Retrovirus-Mediated Correction of the Metabolic Defect in Cultured Farber Disease Cells. Human Gene Therapy, 1999, 10, 1321-1329.	2.7	30
56	A simple method for screening for Farber disease on cultured skin fibroblasts. Clinica Chimica Acta, 1996, 245, 61-71.	1.1	25
57	Allogeneic hematopoietic cell transplantation in Farber disease. Journal of Inherited Metabolic Disease, 0, , .	3.6	4